The prognosis of nodal DLBCL patients with the double expression of MYC and BCL2 treated with R-CHOP therapy was significantly worse in previous studies,7, 8, 9, 10 and it was also shown that the prognosis of patients with the double expression and double hit was not significantly different.7 There is currently no standard therapy for DLBCL patients with the double hit or double expression. Here, DDIT3 is linked to diffuse large B-cell lymphoma.